News, New products, Announcement

Abstract

` We have, in fact, plans in place for several API 4000 LC/ MS/MS systems,’ said Jim Hulse, senior vice president, bioanalytical, MDS Pharma Services. ` The capabilities of the API 4000 are of critical importance. More and more drugs with highly speci® c pharmacological activities and lower daily dosage recommendations are being developed through pharmaceutical pipelines. The lower the dosage recommendation, the greater the sensitivity needed in laboratory instrumentation to analyse samples. The API 4000 will be crucial in determining the safety and eæ cacy of many new drugs. ’